CBLPath to Be Featured at AMP 2012 and in The Journal of Molecular Diagnostics


RYE BROOK, N.Y. — CBLPath is pleased to announce the acceptance of an abstract for poster presentation at the Association for Molecular Pathology (AMP) 2012 Annual Meeting on Genomic Medicine this October. In addition, CBLPath will have a companion piece about the study published in the November 2012 issue of The Journal of Molecular Diagnostics.

Titled “Comparison Studies for the Detection of PTEN Loss in Formalin Fixed Paraffin Embedded Prostate Tissues using Fluorescence in situ Hybridization Technique with 2-, 3- and 4-color Probes,” the abstract will be presented at AMP on Saturday, Oct. 27, from 9:45–10:45 a.m. The 2012 AMP meeting runs from Oct. 25–27 in Long Beach, Calif.

The study’s authors are Amanda LeBlanc, MS, CG (ASCP), Cristina Steele, CG (ASCP), Jasmine Siler, Ruth Aryeequaye and Joseph Benson, M.D., FISUP, FCAP, FASCP, FUSCAP.

The abstract focuses on the detection of PTEN genomic loss by fluorescence in situ hybridization (FISH), which is a clinically applicable tumor marker for prostate cancer. FISH testing performed on routine formalin fixed paraffin embedded (FFPE) tissue samples can present a high level of truncation artifact with an increase in false-positive and false-negative results.

In the study, 2-, 3- and 4-color FISH probes were evaluated on FFPE prostate cancer samples to determine the efficiency of each in detecting PTEN genomic loss.

The sensitivity of the 3- and 4-color probes for heterozygous loss of the PTEN gene surpassed the 2-color probe (9% and 9% versus 16%) whereas the sensitivity of homozygous loss (3–6%) and chromosome loss (19–24%) was similar for all three probes.

Additionally, the 3- and 4-color PTEN probes revealed an increased sensitivity for heterozygous loss due to the additional loci labeled to rule out truncation artifact.

In conclusion, the study showed that the addition of at least one locus to a standard 2-color enumeration probe increased the accuracy of the PTEN FISH assay.

About CBLPath
CBLPath is a national specialty lab with a unique leadership position in the convergence of anatomic, molecular and digital pathology. Beginning from a clinical perspective, we harness molecular testing and digital pathology on an anatomic pathology foundation. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. Through the Best Practice™ Partnership Program we help our pathologist-clients effectively compete against centralized reference laboratories, grow their Practice and remain independent — Keeping Medicine Local™. We provide our subspecialty physician clients comprehensive diagnostics and timely, accurate reports enabling the best patient care. For more about the company, please visit www.CBLPath.com.

About the Association for Molecular Pathology
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the then-emerging field of molecular diagnostics. For more about the organization, visit www.amp.org.

About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics is the official publication of the Association for Molecular Pathology and is co-published by the American Society for Investigative Pathology. For more information about the journal, visit http://journals.elsevierhealth.com/periodicals/jmdi.